Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 1999

View Archived Issues

Study results presented for ViroPharma's antiviral agent pleconaril

Angiotech presents positive results from phase I/II MS study

Exisulind leads to lower PSA levels according to interim phase II/III data

Licensing opportunity from Stanford University: treatment of autoimmune disorders

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

Gliatech files IDE for ADCON-A antiadhesion barrier

PathoGenesis launches TOBI in second market

Company Profile: Onconova Therapeutics

Inspire presents positive results for dry eye disease therapeutic

Antibody-gold cluster conjugates with broad potential application available for licensing

Duramed's conjugated estrogens now available in U.S.

Novo Nordisk presents new insulin delivery system

New selective 5-HT1B receptor antagonists disclosed by Astra (AstraZeneca)

Magainin: Annual Report 1998

Triangle, Glaxo Wellcome and Emory University resolve emtricitabine dispute

Carbapenems from Merck particularly active against methicillin-resistant Gram-positive pathogens

P&G presents new antimicrobial agents with broad spectrum, including resistant bacteria

CETP inhibitors in the Bayer pipeline

Thrombin inhibitors developed by Merck scientists

Second COX-2 inhibitor reaches the market

Cartilage-derived angiogenesis inhibitor is potentially useful in treating proliferative retinopathy

New benzazepine compound selectively inhibits vitronectin receptors

Spanish team develops microsphere delivery system for improved intravitreal use of corticosteroids

Solvay expands cardiovascular product portfolio

European Union approval obtained for Schering-Plough's combination HCV therapy

CoCensys sells holdings in Cytovia

Sunrise Technologies' hyperopia treatment system scheduled for FDA advisory panel review

Enbrel warning related to infections issued by FDA and Immunex

Oral creatine is neuroprotective in transgenic mouse model of ALS

Brain COX-2 expression and arteriolar vasodilatation in response to inflammatory stimuli

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...